Advancing a pipeline of next-generation immunotherapies
Our partnered programs, internal pipeline, and asset library for developers of biologics, vaccines, and T-cell therapeutics.
Neoantigen and shared antigen immunotherapeutics
We are instrumental in the (co-)development of both off-the-shelf and personalized therapeutics using our state-of-the-art ImmunoEngine platform. We have multiple partnered programs ongoing, of which 1 off-the-shelf and 1 personalized cancer vaccine trial have received IND/CTA approval with recruitment underway, and 1 personalized trial is ongoing.
| Partner | Disease | Therapy | Pre-clinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|
| CureVac (BioNTech) | NSCLC | Off-the-shelf mRNA | |||
| CureVac (BioNTech) | Undisclosed | Off-the-shelf mRNA | |||
| University of Liverpool | NSCLC | Personalized DNA | |||
| Undisclosed EU partner | Solid tumors | Personalized DNA | |||
| Undisclosed US partner | Solid tumors | Personalized MVA | |||
Camyotope-targeted and personalized immunotherapeutics
We are advancing our first internal program MNE-C261 in microsatellite-stable colorectal cancer (MSS-CRC) to the clinic with the aim of initiating the clinical phase by H1 2027.
| Program | Disease | Therapy | Target | Pre-clinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|---|
| MNE-C261 | MSS-CRC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX2 | TNBC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX3 | PAAD | Off-the-shelf mRNA | Camyotopes | |||
| MNE-P201 | Solid tumors | Personalized mRNA | Neoantigens | |||
MNE-C261: mRNA-LNP vaccine
- 26 CRC-specific camyotope targets
- Strong polyfunctional immunogenicity
- Very high target abundance: up to 99%
- Exceptional coverage: more than 95%
- Broad HLA-coverage: more than 95%
Multiple other off-the-shelf programs, as well as a personalized program, are in late discovery / early pre-clinical phase.
Unique assets for biologics, vaccine, and T-cell therapeutics developers
We have a broad asset portfolio of MHC-bound and surface antigen targets in a multitude of cancer indications. The targets have been selected and prioritized through use of our ImmunoEngine platform, the best-in-class whole genome target discovery engine. Explore our solutions and publications to see how these targets can be leveraged for your development programs.
Colorectal cancer
Bladder cancer
Breast cancer
Glioblastoma
Pancreatic cancer
Liver cancer
Cervical cancer
Head and neck cancer
